That cannot honestly be answered as a property of the molecule. What reaches patients now is a compounded preparation that has not been reviewed by FDA for safety, effectiveness or quality before marketing, so the answer depends on the preparation, the person and the supervision.

Is sermorelin FDA-approved?

It was approved historically and is not currently supplied as an approved product. We hold its current marketing status in the under-review register rather than asserting it, because the databases that would settle it render results client-side.

What does immunogenicity mean here?

The possibility that the body mounts an immune response to an injected peptide. FDA cites it as a concern for several peptides in this family, influenced by purity and aggregation — which is why manufacturing standards are part of the safety question.

What should a provider check before prescribing?

History and contraindications, interactions with current medicines, whether a growth-hormone-axis intervention is the right frame at all, and what will be monitored afterwards. Axis assessment usually needs more than a single measurement because secretion is pulsatile.

Is it banned in sport?

Growth-hormone-axis compounds fall within the prohibited-substance framework used in tested sport. Check the current prohibited list directly, because the consequences fall on the athlete.

Is sermorelin safe?

This is a fair question with an unsatisfying answer, and the unsatisfying part is the useful part. "Is it safe" is not a property of a molecule — it is a question about a specific preparation, given to a specific person, for a specific reason, under someone's supervision.

What follows is what can honestly be said, what cannot, and what a licensed provider is actually screening for. We do not advise and we do not prescribe.

Current supplyCompounded
Not reviewedPre-marketing
ScreeningProvider-led
WeDo not advise

Why the question has no single answer

Sermorelin was an approved product historically and is not currently supplied that way. What reaches patients now is a compounded preparation, and that changes the safety question in a specific way: the thing in the vial is not a product that has been reviewed by FDA for safety, effectiveness and quality before marketing.

So the honest framing is not "is sermorelin safe" but "what is in this vial, who made it, and is it appropriate for me". Those are three different questions and only the third is about the molecule.

We hold sermorelin's current US marketing status in the under-review register rather than asserting it. The label databases that would settle it render their results in the browser rather than in the page we can retrieve, so we are not in a position to state it as verified fact. Confirm with a licensed provider or pharmacist.

What compounding adds to the risk picture

FDA has been explicit about the general class of concern with compounded peptides, and the reasoning applies whether or not a given compound is named. For several peptides in this family the agency cites risk of immunogenicity for certain routes of administration, complexity in characterising the active ingredient and its peptide-related impurities, and limited or absent human safety data for the proposed routes.

Immunogenicity is worth understanding because it is specific to this class. It refers to the possibility that the body mounts an immune response against an injected peptide — a risk influenced by purity and aggregation, which is precisely what manufacturing standards exist to control.

This is not an argument that every compounded peptide is dangerous. It is an argument that which pharmacy made it, and under what standard, is part of the safety question rather than a procurement detail.

What a licensed provider screens for

A provider working properly in this area is doing several things before anything is prescribed: taking a history that would identify contraindications, considering interactions with what you already take, deciding whether a growth-hormone-axis intervention is even the right frame for your symptoms, and establishing what will be monitored afterwards.

Growth hormone axis assessment is clinician-led and not straightforward. Single measurements are difficult to interpret because secretion is pulsatile, which is why formal assessment generally involves more than one draw or a stimulation protocol rather than one number from a panel.

A service that skips all of this and ships a vial is not screening you. That is the distinction worth caring about.

Questions to ask at consultation

Which pharmacy prepares this, is it a 503A pharmacy or a registered 503B outsourcing facility, and can I see that in writing?
What testing are you basing this on, and how was it collected?
What are you monitoring after I start, and how often?
What are the reasons you would stop or decline this?
What is known about this specific preparation, as opposed to the molecule in general?

If you are competing in a tested sport, growth-hormone-axis compounds fall within the prohibited-substance framework and the consequences are yours rather than the clinic's. Check the current list yourself.

Provenance

Sources

FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — retrieved 2026-08-06
FDA — FD&C Act Provisions that Apply to Human Drug Compounding — retrieved 2026-08-06
FDA — Human Drug Compounding Laws — retrieved 2026-08-06
NIH MedlinePlus — Growth Hormone Tests — retrieved 2026-08-06
WADA — Prohibited List — retrieved 2026-08-06

Questions

Sermorelin safety: common questions

Is sermorelin safe?: That cannot honestly be answered as a property of the molecule. What reaches patients now is a compounded preparation that has not been reviewed by FDA for safety, effectiveness or quality before marketing, so the answer depends on the preparation, the person and the supervision.
Is sermorelin FDA-approved?: It was approved historically and is not currently supplied as an approved product. We hold its current marketing status in the under-review register rather than asserting it, because the databases that would settle it render results client-side.
What does immunogenicity mean here?: The possibility that the body mounts an immune response to an injected peptide. FDA cites it as a concern for several peptides in this family, influenced by purity and aggregation — which is why manufacturing standards are part of the safety question.
What should a provider check before prescribing?: History and contraindications, interactions with current medicines, whether a growth-hormone-axis intervention is the right frame at all, and what will be monitored afterwards. Axis assessment usually needs more than a single measurement because secretion is pulsatile.
Is it banned in sport?: Growth-hormone-axis compounds fall within the prohibited-substance framework used in tested sport. Check the current prohibited list directly, because the consequences fall on the athlete.

Talk to a licensed provider before you buy anything

We do not sell peptides and we do not prescribe. We connect you with licensed providers who can tell you what a compound's actual regulatory status means for you.

Find a licensed provider

TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.

We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.

Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.